Candidates with prediabetes are increasingly accepted as living kidney donors. However, data specific to the outcomes of living kidney donors with prediabetes is scarce. In this study, we aimed to investigate the outcome of living kidney donors with prediabetes. We also aimed to evaluate the utilization of baseline HbA1c to identify donors at high risk for developing diabetes during the post-donation follow-up period.
cancer.Current guidelines recommend active surveillance as the preferred treatment modality for very low risk prostate cancer. However, many fear to offer this alternative to men with germline mutations.
We offer active surveillance as the preferred treatment for men with germline mutations, diagnosed with low risk prostate cancer. The objective of this study is to describe the short term oncologic outcome of active surveillance in this cohort.
METHODS: We perform an extensive screening protocol to all men with germline mutations including: PSA, mpMRI and MRI-US fusion biopsies. In this study we identified patients with germline mutation who were diagnosed with Grade Group 1 prostate cancer, between February 2014 to July 2017. Routine active surveillance follow-up consisted of PSA and DRE every 3 months, mpMRI and a MRI-US fusion confirmatory biopsy within one year of diagnosis. We now report the short term oncologic outcome of this unique group. RESULTS: We identified 12 patients with Grade Group 1 prostate cancer and germline mutations. Eight patients were carriers of mutation in the BRCA genes (4 BRCA1, 4 BRCA2), 4 with germline mutations in CHECK2 and 2 with MSH (Lynch syndrome). Median PSA was 5.2 ng/ml (IQR 3.2-7.6). Median age at diagnosis was 58 years (IQR 52-68). Eleven patients (92%) started active surveillance for prostate cancer. All patients were fully compliant with the follow up protocol. Confirmatory MRI-US fusion biopsies were performed in 9 (81%) patients at a median of 12 months from the initial biopsy. Two of the patients reclassified to Grade Group 2 and seven patients showed no upgrading of ISUP Grade Group. PSA kinetics was unable to predict upgrading.
During the active surveillance period four patients were diagnosed with other malignancies: 1 breast cancer, 2 colon cancer and 1 malignant melanoma. Median follow-up time from the first biopsy is 14 months . Eight patients are still on active surveillance, asymptomatic and without evidence of progressive disease.
CONCLUSIONS: According to these preliminary results, active surveillance is feasible and safe among patients with germline mutations diagnosed with low risk prostate cancer. Carriers in our clinic are monitored very closely, and tend to be compliant. Therefore, the risk that the window of cure is missed is minimal.
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PD55-02 COMPARISON OF TWO PROSPECTIVE COHORTS IN ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER: AFRO-CARIBBEAN VERSUS CAUCASIAN, ONCOLOGIC AND PATHOLOGICAL OUTCOMES
Melanie Percot*, Pointe-A-Pitre/Abymes, France; Gregoire Robert, Jean Philippe Le Pailh, Bordeaux, France -Metropolitan; Gautier Stempfer, Pascal Blanchet, Remi Eyraud, Pointe-A-Pitre/ Abymes, France INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa) is supposedly more agressive among Afro-caribbean men (ACM). We compared oncologic results of active surveillance (AS) in ACM with Caucasian men (CM).
METHODS: We included all consecutive patients who underwent AS in two french centers, 261 ACM between 2005 and 2018 versus 175 CM between 2006 and 2018. Most patients were diagnosed with very low risk PCa (french criterias). Treatment occured in case of histological, biological, MRI progression, or patient demand. We described the curative treatment applied, and analysed histological characteristics after prostatectomy. AS, overall, specific, biochemical recurrence after treatment and metastasis free survivals were compared with the Kaplan-Meier method.
RESULTS: 84.3% ACM and 89.4% CM had very low risk PCa. Median age was 65.3 and 64.6 years, median follow up was 56 and 52 months, respectively. During this time, 48% of ACM and 67% of CM remained on AS. Median AS survival was 58 months for ACM, and not reached at 130 months for CM (fig1). Proportion of patients with biopsic tumoral length progression leading to curative treatment was significatively higher for ACM, 53% versus 37% (p<0.05). 81% of ACM and 62% of CM who underwent treatment had surgery. Poor histological prognosis factors were found in 57 CONCLUSIONS: In our bi-centric study, oncologic outcomes in AS are similar, concerning mortality, recurrence and metastasis, showing availability of actual criterias for ACM. Regarding the higher rate of disease progression in Afro-caribbean population, close monitoring is recommended.
